We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Dynavax has partnered with Taiwan-based Medigen Vaccine Biologics to develop a COVID-19 vaccine candidate. The partners will evaluate Medigen’s recombinant form of the SARS-CoV2 spike protein combined with Dynavax’s CpG1018 adjuvant. Read More
The EMA commissioned the ACCESS project with Utrecht University in May to study data sources and methods that can be used for the postmarketing evaluation of COVID-19 vaccines. Read More
Acadia Pharmaceuticals’ Nuplazid (pimavanserin) failed to meet its primary endpoint in two phase 3 clinical trials evaluating it for major depressive disorder. Read More